NEW YORK (GenomeWeb News) — Biosite will have access to more of Compugen’s diagnostic and immunoassay biomarkers under a renewed and expanded partnership and licensing agreement, Compugen said today.
In June 2005 the companies penned an alliance to develop and commercialize immunoassay-based diagnostics for cardiovascular and oncology indications based on several of Compugen’s gene targets.
Under the new agreement, which covers the same indications, Compugen will receive milestone payments and royalties from product sales that resulted from its contribution.
Compugen also said it will hold the rights to therapeutic applications of targets and antibodies associated with them.